Adoptive CD8+ T-cell immunotherapy of AIDS patients with Kaposi's sarcoma

R. Patarca, N. G. Klimas, J. Walling, D. Sandler, A. Friedlander, X. Q. Jin, M. Nieves Garcia, M. A. Fletcher

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

This article reviews published and original findings from two clinical trials of adoptive CD8+ T-cell immunotherapy of patients with acquired immunodeficiency syndrome (AIDS) and Kaposi's sarcoma (KS). In the first trial, AIDS patients with either KS or oral hairy leukoplakia (OHL) received five rounds of reinfusions of 108-1010 ex vivo expanded and activated autologous CD8+ T cells. Recombinant interleukin-2 (rIL-2) was coadministered only with the fifth and final infusion. Improvement, and in some cases, resolution of OHL, KS, and candidiasis was observed with no side effects. The observation that clinical improvement of KS was more pronounced when reinfusion of CD8+ T cells was followed by rIL-2 infusion led to a second clinical trial designed to examine the effect of repeated infusions of autologous CD8+ T cells with concomitant rIL-2 administration in the treatment of AIDS-related KS. Improvement of KS status was observed in four out of the eight patients studied (three partial and one complete response). The CD8+ T-cell immunotherapy protocol also provided the opportunity to comparatively study CD8+ T-cell-associated genetic programs. Baseline expression patterns of soluble and surface immune markers by CD8+ T cells from AIDS patients and uninfected controls were predominantly of the type 1 type and differed mainly at a quantitative or kinetic level. Deficiencies in immune mediator expression by CD8+ T cells from AIDS patients tended to dissipate with progression through the protocol. Findings are discussed in the context of current knowledge and therapeutic implications of CD8+ T-cell function in AIDS and neoplasia.

Original languageEnglish
Pages (from-to)179-234
Number of pages56
JournalCritical Reviews in Oncogenesis
Volume6
Issue number3-6
StatePublished - Dec 1 1995
Externally publishedYes

Fingerprint

Kaposi's Sarcoma
Immunotherapy
Acquired Immunodeficiency Syndrome
T-Lymphocytes
Hairy Leukoplakia
Interleukin-2
Clinical Trials
Candidiasis
Biomarkers
Therapeutics

Keywords

  • cytotoxicity
  • HIV
  • interleukin-2
  • leukapheresis
  • oral hairy leukoplakia
  • soluble immune mediators
  • T-cell memory
  • type 1 cytokine response

ASJC Scopus subject areas

  • Cancer Research

Cite this

Patarca, R., Klimas, N. G., Walling, J., Sandler, D., Friedlander, A., Jin, X. Q., ... Fletcher, M. A. (1995). Adoptive CD8+ T-cell immunotherapy of AIDS patients with Kaposi's sarcoma. Critical Reviews in Oncogenesis, 6(3-6), 179-234.

Adoptive CD8+ T-cell immunotherapy of AIDS patients with Kaposi's sarcoma. / Patarca, R.; Klimas, N. G.; Walling, J.; Sandler, D.; Friedlander, A.; Jin, X. Q.; Nieves Garcia, M.; Fletcher, M. A.

In: Critical Reviews in Oncogenesis, Vol. 6, No. 3-6, 01.12.1995, p. 179-234.

Research output: Contribution to journalArticle

Patarca, R, Klimas, NG, Walling, J, Sandler, D, Friedlander, A, Jin, XQ, Nieves Garcia, M & Fletcher, MA 1995, 'Adoptive CD8+ T-cell immunotherapy of AIDS patients with Kaposi's sarcoma', Critical Reviews in Oncogenesis, vol. 6, no. 3-6, pp. 179-234.
Patarca R, Klimas NG, Walling J, Sandler D, Friedlander A, Jin XQ et al. Adoptive CD8+ T-cell immunotherapy of AIDS patients with Kaposi's sarcoma. Critical Reviews in Oncogenesis. 1995 Dec 1;6(3-6):179-234.
Patarca, R. ; Klimas, N. G. ; Walling, J. ; Sandler, D. ; Friedlander, A. ; Jin, X. Q. ; Nieves Garcia, M. ; Fletcher, M. A. / Adoptive CD8+ T-cell immunotherapy of AIDS patients with Kaposi's sarcoma. In: Critical Reviews in Oncogenesis. 1995 ; Vol. 6, No. 3-6. pp. 179-234.
@article{50a4ecee7b6f4cf486fac73d901e905d,
title = "Adoptive CD8+ T-cell immunotherapy of AIDS patients with Kaposi's sarcoma",
abstract = "This article reviews published and original findings from two clinical trials of adoptive CD8+ T-cell immunotherapy of patients with acquired immunodeficiency syndrome (AIDS) and Kaposi's sarcoma (KS). In the first trial, AIDS patients with either KS or oral hairy leukoplakia (OHL) received five rounds of reinfusions of 108-1010 ex vivo expanded and activated autologous CD8+ T cells. Recombinant interleukin-2 (rIL-2) was coadministered only with the fifth and final infusion. Improvement, and in some cases, resolution of OHL, KS, and candidiasis was observed with no side effects. The observation that clinical improvement of KS was more pronounced when reinfusion of CD8+ T cells was followed by rIL-2 infusion led to a second clinical trial designed to examine the effect of repeated infusions of autologous CD8+ T cells with concomitant rIL-2 administration in the treatment of AIDS-related KS. Improvement of KS status was observed in four out of the eight patients studied (three partial and one complete response). The CD8+ T-cell immunotherapy protocol also provided the opportunity to comparatively study CD8+ T-cell-associated genetic programs. Baseline expression patterns of soluble and surface immune markers by CD8+ T cells from AIDS patients and uninfected controls were predominantly of the type 1 type and differed mainly at a quantitative or kinetic level. Deficiencies in immune mediator expression by CD8+ T cells from AIDS patients tended to dissipate with progression through the protocol. Findings are discussed in the context of current knowledge and therapeutic implications of CD8+ T-cell function in AIDS and neoplasia.",
keywords = "cytotoxicity, HIV, interleukin-2, leukapheresis, oral hairy leukoplakia, soluble immune mediators, T-cell memory, type 1 cytokine response",
author = "R. Patarca and Klimas, {N. G.} and J. Walling and D. Sandler and A. Friedlander and Jin, {X. Q.} and {Nieves Garcia}, M. and Fletcher, {M. A.}",
year = "1995",
month = "12",
day = "1",
language = "English",
volume = "6",
pages = "179--234",
journal = "Critical Reviews in Oncogenesis",
issn = "0893-9675",
publisher = "Begell House Inc.",
number = "3-6",

}

TY - JOUR

T1 - Adoptive CD8+ T-cell immunotherapy of AIDS patients with Kaposi's sarcoma

AU - Patarca, R.

AU - Klimas, N. G.

AU - Walling, J.

AU - Sandler, D.

AU - Friedlander, A.

AU - Jin, X. Q.

AU - Nieves Garcia, M.

AU - Fletcher, M. A.

PY - 1995/12/1

Y1 - 1995/12/1

N2 - This article reviews published and original findings from two clinical trials of adoptive CD8+ T-cell immunotherapy of patients with acquired immunodeficiency syndrome (AIDS) and Kaposi's sarcoma (KS). In the first trial, AIDS patients with either KS or oral hairy leukoplakia (OHL) received five rounds of reinfusions of 108-1010 ex vivo expanded and activated autologous CD8+ T cells. Recombinant interleukin-2 (rIL-2) was coadministered only with the fifth and final infusion. Improvement, and in some cases, resolution of OHL, KS, and candidiasis was observed with no side effects. The observation that clinical improvement of KS was more pronounced when reinfusion of CD8+ T cells was followed by rIL-2 infusion led to a second clinical trial designed to examine the effect of repeated infusions of autologous CD8+ T cells with concomitant rIL-2 administration in the treatment of AIDS-related KS. Improvement of KS status was observed in four out of the eight patients studied (three partial and one complete response). The CD8+ T-cell immunotherapy protocol also provided the opportunity to comparatively study CD8+ T-cell-associated genetic programs. Baseline expression patterns of soluble and surface immune markers by CD8+ T cells from AIDS patients and uninfected controls were predominantly of the type 1 type and differed mainly at a quantitative or kinetic level. Deficiencies in immune mediator expression by CD8+ T cells from AIDS patients tended to dissipate with progression through the protocol. Findings are discussed in the context of current knowledge and therapeutic implications of CD8+ T-cell function in AIDS and neoplasia.

AB - This article reviews published and original findings from two clinical trials of adoptive CD8+ T-cell immunotherapy of patients with acquired immunodeficiency syndrome (AIDS) and Kaposi's sarcoma (KS). In the first trial, AIDS patients with either KS or oral hairy leukoplakia (OHL) received five rounds of reinfusions of 108-1010 ex vivo expanded and activated autologous CD8+ T cells. Recombinant interleukin-2 (rIL-2) was coadministered only with the fifth and final infusion. Improvement, and in some cases, resolution of OHL, KS, and candidiasis was observed with no side effects. The observation that clinical improvement of KS was more pronounced when reinfusion of CD8+ T cells was followed by rIL-2 infusion led to a second clinical trial designed to examine the effect of repeated infusions of autologous CD8+ T cells with concomitant rIL-2 administration in the treatment of AIDS-related KS. Improvement of KS status was observed in four out of the eight patients studied (three partial and one complete response). The CD8+ T-cell immunotherapy protocol also provided the opportunity to comparatively study CD8+ T-cell-associated genetic programs. Baseline expression patterns of soluble and surface immune markers by CD8+ T cells from AIDS patients and uninfected controls were predominantly of the type 1 type and differed mainly at a quantitative or kinetic level. Deficiencies in immune mediator expression by CD8+ T cells from AIDS patients tended to dissipate with progression through the protocol. Findings are discussed in the context of current knowledge and therapeutic implications of CD8+ T-cell function in AIDS and neoplasia.

KW - cytotoxicity

KW - HIV

KW - interleukin-2

KW - leukapheresis

KW - oral hairy leukoplakia

KW - soluble immune mediators

KW - T-cell memory

KW - type 1 cytokine response

UR - http://www.scopus.com/inward/record.url?scp=0029441351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029441351&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 179

EP - 234

JO - Critical Reviews in Oncogenesis

JF - Critical Reviews in Oncogenesis

SN - 0893-9675

IS - 3-6

ER -